NFE2L2 and cancer: Independent of KEAP1/NRF2/CUL3 mutations, altered protein-protein interactions and KEAP1-inactivating posttranslational modifications also activate NRF2 in cancer, most notably in tissues of the liver, breast, and kidney (9).